Partial
Partially Aligned
Patient Risk:
Medium
Summary
Only some safety claims about complex sleep behaviors are directly supported by the provided zolpidem tartrate tablet labeling excerpts. Multiple other statements (e.g., generic/bioequivalence/patent and pricing claims, insomnia indication frequency, and regulatory requirements) are not supported or contradicted by the supplied label text and therefore are treated as unsupported relative to the provided prescribing information.
Category Scores
Accurate Statements
Zolpidem can cause complex sleep-related behaviors such as sleepwalking.
Boxed Warning (WARNING: COMPLEX SLEEP BEHAVIOUR) and Section 5.1 (Complex Sleep Behaviors) list sleep-walking as a complex sleep behavior.
Zolpidem can cause complex sleep-related behaviors such as sleep-driving.
Boxed Warning (WARNING: COMPLEX SLEEP BEHAVIOUR) and Section 5.1 (Complex Sleep Behaviors) list sleep-driving as a complex sleep behavior.
Complex sleep-related behaviors with zolpidem can occur without full awareness.
Boxed Warning and Section 5.1 state activities may occur while not fully awake and that patients usually do not remember.
Zolpidem can be associated with abuse.
Unsupported Statements
Mylan N.V. manufactures and markets generic versions of zolpidem products.
Not addressed in the provided prescribing information excerpts.
Mylan's zolpidem products include immediate-release formulations of zolpidem tartrate.
Not supported by the provided label excerpts.
Mylan's zolpidem products include extended-release formulations of zolpidem tartrate.
Not supported by the provided label excerpts.
Zolpidem products are commonly prescribed for insomnia.
Indications are provided in the label excerpts, but the claim about common prescribing is not supported by the label text provided.
Once zolpidem patents expire, other pharmaceutical companies, including Mylan, can produce and market generic versions of zolpidem.
Not addressed in the provided prescribing information excerpts.
Introduction of generic versions after patent expiry often leads to lower prices.
Not addressed in the provided prescribing information excerpts.
Generic zolpidem products produced by Mylan are bioequivalent to brand-name counterparts like Ambien.
Bioequivalence/prescribing equivalence for specific generic manufacturer products is not addressed in the provided prescribing information excerpts.
Bioequivalent generic zolpidem products deliver the same amount of active ingredient into the bloodstream over the same period as brand-name counterparts.
Not addressed in the provided prescribing information excerpts.
Bioequivalent generic zolpidem products are therapeutically equivalent to brand-name counterparts.
Not addressed in the provided prescribing information excerpts.
Regulatory bodies, like the U.S. Food and Drug Administration (FDA), require generic drugs to meet stringent standards for safety, efficacy, and quality before approval.
Not addressed in the provided prescribing information excerpts.
Zolpidem can cause daytime drowsiness.
Daytime drowsiness is not included in the provided label excerpts.
Zolpidem can cause dizziness.
Dizziness is not included in the provided label excerpts.
Zolpidem can cause memory impairment.
Memory impairment is not included in the provided label excerpts (the provided excerpts discuss lack of remembrance for complex sleep behaviors, but do not support a general 'memory impairment' claim).
Zolpidem can cause dependence.
Dependence is not included in the provided label excerpts.
Zolpidem can cause complex sleep-related behaviors such as sleepwalking.
Marked as accurate only for the specific complex sleep behaviors; see accurate statements. This entry is intentionally left unsupported only if broader claim is not fully substantiated beyond those excerpts; however the behavior itself is supported.
Zolpidem can cause complex sleep-related behaviors such as sleep-driving.
Marked as accurate only for the specific complex sleep behaviors; see accurate statements. This entry is intentionally left unsupported only if broader claim is not fully substantiated beyond those excerpts; however the behavior itself is supported.
Beyond Mylan, numerous pharmaceutical companies produce generic zolpidem products.
Not addressed in the provided prescribing information excerpts.
Zolpidem can cause memory impairment.
The provided excerpts only state patients usually do not remember complex sleep behaviors; they do not support general memory impairment.
Contradictions
Important Omissions
The provided list does not include the boxed warning elements about serious injury/death and instruction to discontinue immediately upon complex sleep behavior occurrence (for the specific complex sleep behavior claims).
Importance:
Moderate
If the intent was to address complex sleep behaviors fully, the labeling also states they may occur following first or any subsequent use, and may occur with or without alcohol or other CNS depressants; these elements are only partially reflected in the list.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Medium
The response includes some supported complex sleep behavior warnings, but also includes multiple other generalized adverse-effect claims not supported by the provided label excerpts. Missing some boxed-warning specificity (injury/death and immediate discontinuation) could reduce risk communication accuracy.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Several statements are unrelated to the provided zolpidem tartrate tablet label excerpts (e.g., Mylan/generic market claims, bioequivalence, pricing) and multiple safety claims are not supported by the excerpts (e.g., daytime drowsiness, dizziness, dependence).
Suggested Improvement
Restrict label-based claims to what is present in the provided excerpts (especially complex sleep behaviors per Boxed Warning and Section 5.1, including serious injury/death and immediate discontinuation). Remove or qualify non-label manufacturing/generic/patent/pricing and unsupported adverse-effect statements.